Hospital Budget Implications of Substituting Dabigatran for Warfarin in an Anticoagulation Service

The aim of our study was to assess hospital budget implications of substituting dabigatran for warfarin in patients enrolled in a large anticoagulation service. The study population was identified using criteria from randomized controlled trials of dabigatran. We obtained labor costs ($ 483 per patient) from the hospital's anticoagulation service budget, laboratory costs of international normalized ratio (INR) tests ($ 267 per patient), and wholesale costs of warfarin 5 mg tablets ($ 31 per patient) and dabigatran 150 mg capsules ($ 2464 per patient). A total of 1774 (93.5%) of 1898 patients were eligible to substitute dabigatran for warfarin. The annual projected hospital expense for anticoagulation with dabigatran was $ 4 371 136, attributable to drug cost alone. The annual projected cost of warfarin management was $ 1 385 494. This was comprised of $ 856 842 for labor, $ 473 658 for INR testing, and $ 54 994 for the drug cost of warfarin. Substitution will result in increased expense due to drug cost.